by Keyword: Diabetes

By year:[ 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 ]

Lanzalaco, S., Fabregat, G., Muñoz-Galan, H., Cabrera, J., Muñoz-Pascual, X., Llorca, J., Alemán, C., (2020). Recycled low-density polyethylene for noninvasive glucose monitoring: A proposal for plastic recycling that adds technological value ACS Sustainable Chemistry and Engineering 8, (33), 12554-12560

In this work, we present a successful strategy to convert recycled LDPE films, which usually end up in landfills or leak into the environment, into an advanced biomedical product. More specifically, LDPE films for food packaging have been treated with atmosphere corona discharge plasma for electrochemical detection of glucose. Enzyme-functionalized sensors manufactured using such recycled materials, which act as a mediator capable of electrocommunicating with the glucose oxidase (GOx) enzyme, are able to detect glucose concentrations in sweat and are fully compatible with the levels of such bioanalytes in both healthy and diabetic patients. Covalent immobilization of the GOx enzyme on the plasma-treated LDPE films has been successfully performed using the carbodiimide method, as proved by X-ray photoelectron spectroscopy. Then, the electronic communication between the deeply buried active site of the GOx and the reactive excited species formed at the surface of the plasma-treated LDPE has been demonstrated by linear sweep voltammetry. Finally, cyclic voltammetry in artificial sweat has been used to show that the LDPE-functionalized sensor has a linear response in the concentration of range of 50 μM to 1 mM with a limit of detection of 375 μA·μM–1·cm–2. Comparison of the performance of sensors prepared using recycled (i.e. with additives) and pristine (i.e. without additives) LDPE indicates that the utilization of the former does not require any pretreatment to eliminate additives. The present strategy demonstrates a facile approach for recycling LDPE waste into a high value-added product, which will potentially pave the way for the treatment of plastic waste in the future. Noninvasive glucose sensors based on recycled LDPE may play a crucial role in monitoring diabetes in underdeveloped regions.

Keywords: Biosensors, Diabetes monitoring, High-value recycling, Plasma treatment, Sweat sensors

Oller-Moreno, Sergio, Cominetti, Ornella, Galindo, Antonio Núñez, Irincheeva, Irina, Corthésy, John, Astrup, Arne, Saris, Wim H. M., Hager, Jörg, Kussmann, Martin, Dayon, Loïc, (2018). The differential plasma proteome of obese and overweight individuals undergoing a nutritional weight loss and maintenance intervention PROTEOMICS - Clinical Applications 12, (1), 1600150

Purpose : The nutritional intervention program “DiOGenes” focuses on how obesity can be prevented and treated from a dietary perspective. We generated differential plasma proteome profiles in the DiOGenes cohort to identify proteins associated with weight loss and maintenance and explore their relation to body mass index, fat mass, insulin resistance and sensitivity. Experimental Design : Relative protein quantification was obtained at baseline and after combined weight loss/maintenance phases using isobaric tagging and MS/MS. A Welch t-test determined proteins differentially present after intervention. Protein relationships with clinical variables were explored using univariate linear models, considering collection center, gender and age as confounding factors. Results : 473 subjects were measured at baseline and end of the intervention; 39 proteins were longitudinally differential. Proteins with largest changes were sex hormone-binding globulin, adiponectin, C-reactive protein, calprotectin, serum amyloid A, and proteoglycan 4 (PRG4), whose association with obesity and weight loss is known. We identified new putative biomarkers for weight loss/maintenance. Correlation between PRG4 and proline-rich acidic protein 1 (PRAP1) variation and Matsuda insulin sensitivity increment was showed. Conclusions and Clinical Relevance : MS-based proteomic analysis of a large cohort of non-diabetic overweight and obese individuals concomitantly identified known and novel proteins associated with weight loss and maintenance.

Keywords: Biomarker, Diabetes, Large-scale study, Mass spectrometry, Obesity, Proteomics

Juanola-Feliu, Esteve, Colomer-Farrarons, Jordi, Miribel-Català, Pere, González-Piñero, Manel, Samitier, Josep, (2014). Nano-enabled implantable device for glucose monitoring Implantable Bioelectronics (ed. Katz, Evgeny), Wiley-VCH Verlag GmbH & Co. KGaA (Weinheim, Germany) , 247-263

This chapter contains sections titled: * Introduction * Biomedical Devices for In Vivo Analysis * Conclusions and Final Recommendations * References

Keywords: Technology transfer, Innovation management, Nanotechnology, Nanobiosensor, Diabetes, Biomedical device, Implantable biosensors

Juanola-Feliu, E., Colomer-Farrarons, J., Miribel-Català , P., Samitier, J., Valls-Pasola, J., (2012). Market challenges facing academic research in commercializing nano-enabled implantable devices for in-vivo biomedical analysis Technovation , 32, (3-4), 193-204

This article reports on the research and development of a cutting-edge biomedical device for continuous in-vivo glucose monitoring. This entirely public-funded process of technological innovation has been conducted at the University of Barcelona within a context of converging technologies involving the fields of medicine, physics, chemistry, biology, telecommunications, electronics and energy. The authors examine the value chain and the market challenges faced by in-vivo implantable biomedical devices based on nanotechnologies. In so doing, they trace the process from the point of applied research to the final integration and commercialization of the product, when the social rate of return from academic research can be estimated. Using a case-study approach, the paper also examines the high-tech activities involved in the development of this nano-enabled device and describes the technology and innovation management process within the value chain conducted in a University-Hospital-Industry-Administration-Citizens framework. Here, nanotechnology is seen to represent a new industrial revolution, boosting the biomedical devices market. Nanosensors may well provide the tools required for investigating biological processes at the cellular level in vivo when embedded into medical devices of small dimensions, using biocompatible materials, and requiring reliable and targeted biosensors, high speed data transfer, safely stored data, and even energy autonomy.

Keywords: Biomedical device, Diabetes, Innovation management, Nanobiosensor, Nanotechnology, Research commercialization, Technology transfer, Academic research, Applied research, Barcelona, Biocompatible materials, Biological process, Biomedical analysis, Biomedical devices, Cellular levels, Converging technologies, Glucose monitoring, High-speed data transfer, Implantable biomedical devices, Implantable devices, In-vivo, Industrial revolutions, Innovation management, Medical Devices, Nanobiosensor, Rate of return, Research and development, Technological innovation, Value chains, Biological materials, Biomedical engineering, Biosensors, Commerce, Data transfer, Earnings, Engineering education, Glucose, Implants (surgical), Industrial research, Innovation, Medical problems, Nanosensors, Nanotechnology, Technology transfer, Equipment

Perán, M., Sánchez-Ferrero, A., Tosh, D., Marchal, J. A., Lopez, E., Alvarez, P., Boulaiz, H., Rodríguez-Serrano, F., Aranega, A., (2011). Ultrastructural and molecular analyzes of insulin-producing cells induced from human hepatoma cells Cytotherapy , 13, (2), 193-200

Background aims. Diabetes type I is an autoimmune disease characterized by the destruction of pancreatic insulin-producing (beta-) cells and resulting in external insulin dependence for life. Islet transplantation represents a potential treatment for diabetes but there is currently a shortage of suitable organs donors. To augment the supply of donors, different strategies are required to provide a potential source of beta-cells. These sources include embryonic and adult stem cells as well as differentiated cell types. The main goal of this study was to induce the transdifferentiation (or conversion of one type cell to another) of human hepatoma cells (HepG2 cells) to insulin-expressing cells based on the exposure of HepG2 cells to an extract of rat insulinoma cells (RIN). Methods. HepG2 cells were first transiently permeabilized with Streptolysin O and then exposed to a cell extract obtained from RIN cells. Following transient exposure to the RIN extract, the HepG2 cells were cultured for 3 weeks. Results. Acquisition of the insulin-producing cell phenotype was determined on the basis of (i) morphologic and (ii) ultrastructural observations, (iii) immunologic detection and (iv) reverse transcription (RT)-polymerase chain reaction (PCR) analysis. Conclusions. This study supports the use of cell extract as a feasible method for achieve transdifferentiation of hepatic cells to insulin-producing cells.

Keywords: Beta-cells, Diabetes, Insulin-producing cells, Transdifferentiation

Valente, T., Gella, A., Fernàndez-Busquets, X., Unzeta, M., Durany, N., (2010). Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus Neurobiology of Disease , 37, (1), 67-76

It has been extensively reported that diabetes mellitus (DM) patients have a higher risk of developing Alzheimer's disease (AD). but a mechanistic connection between both pathologies has not been provided so far Carbohydrate-derived advanced glycation endproducts (AGEs) have been implicated in the chronic complications of DM and have been reported to play an important role in the pathogenesis of AD. The earliest histopathological manifestation of AD is the apparition of extracellular aggregates of the amyloid beta peptide (A beta). To investigate possible correlations between AGEs and A beta aggregates with both pathologies. we have performed an immuhistochemical study in human post-mortem samples of AD, AD with diabetes (ADD). diabetic and nondemented controls ADD brains showed increased number of A beta dense plaques and receptor for AGEs (RACE)-positive and Tau-positive cells, higher AGEs levels and major microglial activation, compared to AD brain. Our results indicate that ADD patients present a significant increase of cell damage through a RAGE-dependent mechanism, suggesting that AGEs may promote the generation of an oxidative stress vicious cycle, which can explain the severe progression of patients with both pathologies.

Keywords: Abeta, Alzheimer's disease, Rage, Ages, Diabetes, Immunohistochemistry, Advanced glycation endproducts, Beta-amyloid peptide, End-products, Oxidative stress, Advanced glycosylation, Synaptic dysfunction, Cross-linking